Novartis news

Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer after failure of targeted therapy

Novartis begins shipment of Fluvirin® seasonal influenza vaccine for the U.S. market ahead of schedule

Ilaris® recommended for European approval as new biologic drug to treat a rare but serious group of auto-inflammatory diseases

FDA approves Tekturna HCT® as initial treatment in patients unlikely to achieve their blood pressure goal with a single agent

Novartis delivers strong operational performance in the first half of 2009 driven by sustained Pharmaceuticals innovation

Japanese Ministry of Health approves Rasilez®, a first-in-class direct renin inhibitor (DRI), for the treatment of high blood pressure

Novartis extends tuberculosis drug donation to Tanzania

Novartis delivers 250,000,000th Coartem® treatment and becomes first healthcare company to join United Against Malaria partnership

Novartis receives Complete Response letter from the US Food and Drug Administration for its investigational vaccine Menveo®

Once-yearly Aclasta® approved in EU to treat osteoporosis caused by steroid treatment in men and postmenopausal women

Syndicate content